Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Review ArticlePractice

Hypocalcemia

Updates in diagnosis and management for primary care

Jeremy Fong and Aliya Khan
Canadian Family Physician February 2012, 58 (2) 158-162;
Jeremy Fong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aliya Khan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: aliya@mcmaster.ca
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Objective To provide family physicians with an evidence-based approach to the diagnosis and management of hypocalcemia.

Quality of evidence MEDLINE and EMBASE articles from 2000 to 2010 were searched, with a focus on the diagnosis and management of hypocalcemia. Levels of evidence (I to III) were cited where appropriate, with most studies providing level II or III evidence. References of pertinent papers were also searched for relevant articles.

Main message Chronic hypocalcemia is commonly due to inadequate levels of parathyroid hormone or vitamin D, or due to resistance to these hormones. Treatment focuses on oral calcium and vitamin D supplements, as well as magnesium if deficiency is present. Treatment can be further intensified with thiazide diuretics, phosphate binders, and a low-salt and low-phosphorus diet when treating hypocalcemia secondary to hypoparathyroidism. Acute and life-threatening calcium deficit requires treatment with intravenous calcium. The current treatment recommendations are largely based on expert clinical opinion and published case reports, as adequately controlled clinical trial data are not currently available. Complications of current therapies for hypoparathyroidism include hypercalciuria, nephrocalcinosis, renal impairment, and soft tissue calcification. Current therapy is limited by serum calcium fluctuations. Although these complications are well recognized, the effects of therapy on overall well-being, mood, cognition, and quality of life, as well as the risk of complications, have not been adequately studied.

Conclusion Family physicians play a crucial role in educating patients about the long-term management and complications of hypocalcemia. Currently, management is suboptimal and marked by fluctuations in serum calcium and a lack of approved parathyroid hormone replacement therapy for hypoparathyroidism.

Hypocalcemia is a common biochemical abnormality that can range in severity from being asymptomatic in mild cases to presenting as an acute life-threatening crisis.1 Serum calcium levels are regulated within a narrow range (2.1 to 2.6 mmol/L) by 3 main calcium-regulating hormones—parathyroid hormone (PTH), vitamin D, and calcitonin—through their specific effects on the bowel, kidneys, and skeleton.1,2 Approximately half of the total serum calcium is bound to protein, and the remaining free ionized calcium is physiologically active.2 Serum calcium levels must be corrected for the albumin level before confirming the diagnosis of hypercalcemia or hypocalcemia.1

Hypocalcemia (corrected serum total calcium level < 2.12 mmol/L) is most commonly a consequence of vitamin D inadequacy or hypoparathyroidism, or a resistance to these hormones1,3 (Box 11,2,4,5). Hypocalcemia has also been associated with many drugs, including bisphosphonates, cisplatin, antiepileptics, aminoglycosides, diuretics, and proton pump inhibitors (level III evidence); as well, there are other causes.3

Quality of evidence

We searched MEDLINE and EMBASE for articles published between 2000 and 2010 with a focus on the diagnosis and management of hypocalcemia. Most peer-reviewed studies offered level II and level III evidence. References of pertinent papers were also searched for relevant articles.

Main message

Low vitamin D levels

The presence of 1,25-dihydroxyvitamin D enhances intestinal absorption of calcium and phosphorus, and promotes bone remodeling.4,6 Vitamin D inadequacy (25-hydroxyvitamin D [25(OH)D] level < 75 nmol/L) remains common in children and adults.1,2,4,7,8 Inadequate vitamin D levels lead to a reduction in gastrointestinal calcium absorption of up to 50%, resulting in only 10% to 15% of dietary intestinal calcium being absorbed.4

Vitamin D inadequacy is also caused by reduced skin synthesis (owing to limited sun exposure, skin pigmentation, or skin thinning with age). Decreased absorption, increased catabolism, impaired hepatic or renal hydroxylation to form 1,25-dihydroxyvitamin D, or acquired and genetic disorders of vitamin D metabolism and responsiveness also lead to low vitamin D levels.1,2,4,7 Vitamin D requirements increase during and after pregnancy, and low maternal vitamin D levels are associated with hypocalcemia in breastfed infants.9

Box 1.

Causes of hypocalcemia

The causes of hypocalcemia include the following:
  • Vitamin D inadequacy or vitamin D resistance

  • Hypoparathyroidism following surgery

  • Hypoparathyroidism owing to autoimmune disease or genetic causes

  • Renal disease or end-stage liver disease causing vitamin D inadequacy

  • Pseudohypoparathyroidism or pseudopseudohypoparathyroidism

  • Metastatic or heavy metal (copper, iron) infiltration of the parathyroid gland

  • Hypomagnesemia or hypermagnesemia

  • Sclerotic metastases

  • Hungry bone syndrome postparathyroidectomy

  • Infusion of phosphate or citrated blood transfusions

  • Critical illness

  • Drugs (eg, high-dose intravenous bisphosphonates)

  • Fanconi syndrome

  • Past radiation of parathyroid glands

  • Data from Cooper and Gittoes,1 Murphy and Williams,2 Holick,4 and Bilezikian.5

  • Levels of evidence

    Level I: At least one properly conducted randomized controlled trial, systematic review, or meta-analysis

    Level II: Other comparison trials, non-randomized, cohort, case-control, or epidemiologic studies, and preferably more than one study

    Level III: Expert opinion or consensus statements

    Hypocalcemia can develop in individuals with inadequate 25(OH)D levels following initiation of bisphosphonate therapy and should be excluded before starting intravenous bisphosphonate therapy, particularly in individuals with osteoblastic metastases (level III10–13 and level I14 evidence). Serum 25(OH)D and 1,25-dihydroxyvitamin D levels should be measured in individuals with hypocalcemia (level III evidence).2

    Reduced or inappropriately normal PTH

    Low PTH levels result in excessive urinary calcium losses, decreased bone remodeling, and reduced intestinal calcium absorption.1,15 Rarely, PTH resistance in the form of pseudohypoparathyroidism can produce a similar physiologic profile and should be considered in the presence of an elevated serum PTH level.1

    Hypoparathyroidism is most commonly seen following inadvertent removal of or damage to the parathyroid glands or their vascular supply during a total thyroidectomy. This occurs in 0.5% to 6% of total thyroidectomies.16 Persistent hypocalcemia 6 months after surgery confirms the diagnosis of hypoparathyroidism in the presence of low or inappropriately normal PTH levels.

    Autoimmune hypoparathyroidism can present alone or as part of a polyglandular endocrinopathy.1,2,16,17 Genetic mutations involving the development of the parathyroid glands, and synthesis or secretion of PTH can also cause hypoparathyroidism. Genetic mutations can also result in resistance to PTH at the proximal renal tubule, causing excessive renal calcium losses and hypocalcemia.2,16,17 Activating mutations of the calcium-sensing receptor are among the most common causes of congenital hypoparathyroidism. These mutations are marked by the presence of considerable hypercalciuria, typically increased by administration of vitamin D metabolites.2,16–23

    Other congenital abnormalities

    Abnormalities in the embryonic development of the parathyroid glands can result in DiGeorge syndrome, which can be associated with cardiac defects, abnormal facies, thymic hypoplasia, cleft palate, and hypocalcemia. Other genetic abnormalities can also cause hypoparathyroidism or pseudoparahyperthyroidism.

    Uncommon causes of hypoparathyroidism include heavy metal infiltration of the parathyroid glands with iron, as seen in hemochromatosis, or thalassemia. Copper deposition as seen in Wilson disease is also an uncommon cause, as is metastatic infiltration of the parathyroid glands. Magnesium deficiency or excess can impair PTH secretion and also result in hypoparathyroidism.10

    Clinical presentation and evaluation

    Acute hypocalcemia can result in severe symptoms requiring hospitalization, whereas patients who gradually develop hypocalcemia are more likely to be asymptomatic.1 Symptoms of hypocalcemia most commonly include paresthesia, muscle spasms, cramps, tetany, circumoral numbness, and seizures.1,2,16 Hypocalcemia can also present with laryngospasm, neuromuscular irritability, cognitive impairment, personality disturbances, prolonged QT intervals, electrocardiographic changes that mimic myocardial infarction, or heart failure.2,16

    It is essential to ask about family history of hypocalcemia as this can indicate a genetic cause for the hypoparathyroidism. Previous head or neck surgery needs to be confirmed. Growth or mental retardation, congenital anomalies, or hearing loss also suggest the presence of a genetic abnormality.16 On physical examination, look for neck scarring, as patients might not recall remote neck surgery. Chvostek and Trousseau signs can be elicited in patients with hypocalcemia. Chvostek sign is the twitching of the upper lip with tapping on the cheek 2 cm anterior to the earlobe, below the zygomatic process overlying the facial nerve.24 Trousseau sign (a more reliable sign present in 94% of hypocalcemic individuals and only 1% to 4% of healthy people) is the presence of carpopedal spasm observed following application of an inflated blood pressure cuff over systolic pressure for 3 minutes in hypocalcemic patients.24,25

    Diagnostic laboratory investigations: Initial laboratory investigations are outlined in Box 2.1,2,16 Hypoparathyroid patients will have hypocalcemia, low or inappropriately normal PTH levels, hyperphosphatemia, hypercalciuria, and low 1,25-dihydroxyvitamin D3 levels.16 Measuring ionized calcium is highly recommended in critically ill patients, as variation in serum pH affects calcium binding to albumin (level II evidence).26–28

    Acute management of hypocalcemia

    Intravenous calcium is given if serum calcium levels fall below 1.9 mmol/L, or ionized calcium levels are less than 1 mmol/L, or if patients are symptomatic (level III evidence).1,2,29 Intravenous calcium gluconate administered with a central venous catheter is preferable to avoid extravasation and irritation of the surrounding tissue, which is most often seen with calcium chloride administration.1,2,16,30,31 Intravenous calcium is given as 1 or 2 10-mL ampoules of 10% calcium gluconate diluted in 50 to 100 mL 5% dextrose, infused over 5 to 10 minutes (level III evidence).1,2 To avoid precipitation of calcium salts, phosphate and bicarbonate should not be infused with the calcium (level III evidence).30 Patients should also receive oral calcium supplements and calcitriol (0.25 to 1 μg/day) as needed (level III evidence).1 Magnesium deficiency or alkalosis should be corrected if present.2,16,18 Acutely, magnesium supplementation therapy will not elevate serum PTH or calcium, as peripheral PTH resistance can last for several days.30

    Rapid correction of hypocalcemia can contribute to cardiac arrhythmia.1,3 Cardiac monitoring during intravenous calcium supplementation is necessary, particularly in patients taking digoxin therapy (level III evidence).1,16,18

    Long-term management of chronic hypocalcemia

    Oral calcium and vitamin D and its metabolites are essential in management, in addition to correction of hypomagnesemia.2 Calcium carbonate and calcium citrate have the greatest proportion of elemental calcium (40% and 28%, respectively) and are easily absorbed; they are considered the supplements of choice.6,16,32 Calcium supplement dosages are 1 to 2 g of elemental calcium 3 times daily (level III evidence).16 Elemental calcium supplements can be started at 500 to 1000 mg 3 times daily and titrated upward (level III evidence).16 Asymptomatic electrocardiography changes usually normalize with calcium and calcitriol supplementation (level II evidence).33

    Hypercalciuria is a complication of vitamin D therapy, particularly for patients with hypoparathyroidism, as the absence of PTH enhances urinary calcium losses.2 If hypocalcemia is due to malabsorption of vitamin D, physicians should treat the underlying cause (eg, implementing a gluten-free diet for patients with celiac disease).34 Magnesium supplementation corrects hypomagnesemia-related hypocalcemia.3

    Box 2.

    Basic investigations to establish a specific diagnosis, along with more specialized tests that might be required in specific cases (level III evidence)

    Basic investigations
    • Serum calcium (corrected for albumin)

    • Phosphate

    • Magnesium

    • Electrolytes

    • Creatinine

    • Alkaline phosphatase

    • Parathyroid hormone

    • 25-hydroxyvitamin D

    • Serum pH

    • Complete blood count

    Further investigations
    • Ionized calcium

    • 24-hour urinary phosphate, calcium, magnesium, and creatinine

    • 1,25-dihydroxyvitamin D

    • Renal ultrasonography to assess for nephrolithiasis

    • DNA sequencing to exclude genetic mutations

    • Biochemistry in first-degree family members

  • Data from Cooper and Gittoes,1 Murphy and Williams,2 Shoback.16

  • Vitamin D inadequacy: Vitamin D inadequacy requires correction with either ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3). Ergocalciferol can be given in doses of 50 000 IU weekly or twice a week with assessment of levels 3 months later, titrating up until a normal 25(OH)D level is reached (level III,1,4,8 level II,35,36 and level I37 evidence). Alternatively, 300 000 IU of ergocalciferol can be administered intramuscularly, with the first 2 injections spaced 3 months apart, followed by regular injections every 6 months (level III evidence).1,2

    Cholecalciferol is more potent than ergocalciferol.4,6,16,38,39 Administrating 100 000 IU of vitamin D3 once every 3 months is also effective in maintaining adequate 25(OH)D levels (level I evidence).40 Further study is needed to evaluate the use of tanning beds in correcting vitamin D inadequacy (level III evidence).4,41

    Hypoparathyroidism: The treatment of hypoparathyroidism requires careful evaluation of the patient and consideration of the treatment options other than calcium supplementation. The primary goals of management with calcium and vitamin D supplementation include symptom control, maintaining serum calcium in the low-normal range (2.00 to 2.12 mmol/L), maintaining serum phosphorus within a normal range, and maintaining a calcium-phosphate product below 4.4 mmol2/L2 (55 mg2/dL2) without developing hypercalciuria, nephrocalcinosis, or precipitation of calcium-phosphate salts in soft tissues (level III evidence).2,16,18,42

    Vitamin D analogues, particularly calcitriol or alfacalcidol, can be used.2 Usual starting doses are 0.5 μg of calcitriol or 1 μg of alfacalcidol daily.1 Upward titration with increases in the doses every 4 to 7 days is advised until a low-normal serum calcium level is achieved (level III evidence).1 Calcitriol is preferable as it is relatively more potent, and has a rapid onset and offset of action attributable to its short half-life.2,6,16 Vitamin D treatment in patients with gain-of-function mutations of the calcium-sensing receptors results in further hypercalciuria, nephrocalcinosis, and renal impairment; thus, asymptomatic patients can simply be followed.2

    Thiazide diuretics decrease urinary calcium excretion by increasing distal renal tubular calcium reabsorption.2,16,43 Combining diuretics with a low-salt, low-phosphate diet and phosphate binders is beneficial (level III evidence).6

    Serum calcium, phosphorus, and creatinine should be measured weekly to monthly during initial dose adjustments, with quarterly or twice-yearly measurements once the therapy protocol has stabilized (level III evidence).1,6,16

    Unfortunately, patients with hypoparathyroidism have poor quality of life as measured on standard scales, which illustrates the limitations of therapy (level II evidence).44

    Replacement therapy with PTH is a viable option, as it corrects hypercalciuria and potentially reduces the risk of nephrocalcinosis, nephrolithiasis, and renal insufficiency. It can also reduce the wide fluctuation in serum calcium as well as the need to administer very large doses of calcium and vitamin D metabolites. Also, PTH 1-34 reduces urinary calcium excretion (level II evidence),45–49 possibly allowing reductions in the dose of calcium and vitamin D; PTH 1-84 has also been studied and might become a valuable addition to current treatment options (level II evidence).50 Hypoparathyroidism is the only remaining hormonal insufficiency that is currently not being treated with direct replacement of the deficient hormone.51 At this time, PTH supplementation has not been approved by Health Canada for the treatment of hypoparathyroidism.2

    Conclusion

    Family physicians play a key role in the management of hypocalcemia and hypoparathyroidism. Management requires identification of the cause of hypocalcemia, followed by calcium and vitamin D metabolite supplementation. Treatment can be further enhanced by introducing thiazide diuretics and other options, which are effective in treating hypocalcemia and preventing symptoms. Unfortunately, current evidence is largely based on clinical experience rather than controlled comparison trials. Conventional therapy for hypoparathyroidism is currently suboptimal and is associated with wide fluctuations in serum calcium, as well as the risks of hypercalciuria, renal impairment, and hypercalcemia. Following evaluation and determination of the cause of hypocalcemia, physicians should treat aggressively and closely monitor patients.

    Notes

    KEY POINTS

    Family physicians play a key role in managing hypocalcemia and hypoparathyroidism, one of the main causes of hypocalcemia. Conventional therapy for hypocalcemia is currently suboptimal. Treatment for hypoparathyroidism is hampered by the lack of an approved parathyroid hormone replacement therapy. This article reviews the literature regarding the causes of hypocalcemia, including vitamin D deficiency and congenital and acquired causes of hypoparathyroidism, as well as key issues in management, such as intravenous administration of calcium for acute hypocalcemia, and vitamin D and calcium supplementation for chronic hypocalcemia.

    Footnotes

    • This article is eligible for Mainpro-M1 credits. To earn credits, go to www.cfp.ca and click on the Mainpro link.

    • La traduction en français de cet article se trouve à www.cfp.ca dans la table des matières du numéro de février 2012 à la page e92.

    • This article has been peer reviewed.

    • Contributors

      Mr Fong and Dr Khan contributed to the literature review and interpretation, and to preparing the manuscript for submission.

    • Competing interests

      None declared

    • Copyright© the College of Family Physicians of Canada

    References

    1. ↵
      1. Cooper MS,
      2. Gittoes NJ
      . Diagnosis and management of hypocalcaemia. BMJ 2008;336(7656):1298-302.
      OpenUrlFREE Full Text
    2. ↵
      1. Murphy E,
      2. Williams GR
      . Hypocalcaemia. Medicine 2009;37(9):465-8.
      OpenUrl
    3. ↵
      1. Liamis G,
      2. Milionis HJ,
      3. Elisaf M
      . A review of drug-induced hypocalcemia. J Bone Miner Metab 2009;27(6):635-42.
      OpenUrlCrossRefPubMed
    4. ↵
      1. Holick MF
      . Vitamin D deficiency. N Engl J Med 2007;357(3):266-81.
      OpenUrlCrossRefPubMed
    5. ↵
      1. Bilezikian JP,
      2. Khan A,
      3. Potts JT Jr.,
      4. Brandi ML,
      5. Clark BL,
      6. Shoback D,
      7. et al
      . Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 2011;26(10):2317-37.doi:10.1002/jbmr.483
      OpenUrlCrossRefPubMed
    6. ↵
      1. Walker Harris V,
      2. Jan De Beur S
      . Postoperative hypoparathyroidism: medical and surgical therapeutic options. Thyroid 2009;19(9):967-73.
      OpenUrlCrossRefPubMed
    7. ↵
      1. Noto H,
      2. Heller HJ
      . Vitamin D deficiency as an ignored cause of hypocalcemia in acute illness: report of 2 cases and review of literature. Open Endocrinol J 2009;3:1-4.
      OpenUrl
    8. ↵
      1. Holick MF
      . High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006;81(3):353-73.
      OpenUrlCrossRefPubMed
    9. ↵
      1. Mughal MZ,
      2. Salama H,
      3. Greenaway T,
      4. Laing I,
      5. Mawer EB
      . Lesson of the week: florid rickets associated with prolonged breast feeding without vitamin D supplementation. BMJ 1999;318(7175):39-40.
      OpenUrlFREE Full Text
    10. ↵
      1. Rosen CJ,
      2. Brown S
      . Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 2003;348(15):1503-4.
      OpenUrlCrossRefPubMed
      1. Peter R,
      2. Mishra V,
      3. Fraser WD
      . Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ 2004;328(7435):335-6.
      OpenUrlFREE Full Text
      1. Mishra A,
      2. Wong L,
      3. Jonklaas J
      . Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine 2001;14(2):159-64.
      OpenUrlCrossRefPubMed
    11. ↵
      1. Yazbeck CF,
      2. Gonzalez-Angulo AM,
      3. Shaw SA,
      4. Waguespack SG,
      5. Vassilopoulou-Sellin R,
      6. Busaidy NL
      . Hypocalcemia induced by bisphophonates in cancer patients with vitamin D deficiency [2007 ASCO Annual Meeting abstract 19644]. J Clin Oncol 2007;25(18 Suppl):19644.
      OpenUrl
    12. ↵
      1. Kohno N,
      2. Aogi K,
      3. Minami H,
      4. Nakamura S,
      5. Asaga T,
      6. Iino Y,
      7. et al
      . Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23(15):3314-21. Epub 2005 Feb 28.
      OpenUrlAbstract/FREE Full Text
    13. ↵
      1. Khan A,
      2. Bilezikian J
      . Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ 2000;163(2):184-7.
      OpenUrlAbstract/FREE Full Text
    14. ↵
      1. Shoback D
      . Clinical practice. Hypoparathyroidism. N Engl J Med 2008;359(4):391-403.
      OpenUrlCrossRefPubMed
    15. ↵
      1. Marx SJ
      . Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 2000;343(25):1863-75.
      OpenUrlCrossRefPubMed
    16. ↵
      1. Maeda SS,
      2. Fortes EM,
      3. Oliveira UM,
      4. Borba VC,
      5. Lazaretti-Castro M
      . Hypoparathyroidism and pseudohypoparathyroidism. Arq Bras Endocrinol Metabol 2006;50(4):664-73.
      OpenUrlPubMed
      1. Shiohara M,
      2. Shiozawa R,
      3. Kurata K,
      4. Matsuura H,
      5. Arai F,
      6. Yasuda T,
      7. et al
      . Effect of parathyroid hormone administration in a patient with severe hypoparathyroidism caused by gain-of-function mutation of calcium-sensing receptor. Endocr J 2006;53(6):797-802. Epub 2006 Sep 19.
      OpenUrlPubMed
      1. Egbuna OI,
      2. Brown EM
      . Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol 2008;22(1):129-48.
      OpenUrlCrossRefPubMed
      1. Herwadkar A,
      2. Gennery AR,
      3. Moran AS,
      4. Haeney MR,
      5. Arkwright PD
      . Association between hypoparathyroidism and defective T cell immunity in 22q11.2 deletion syndrome. J Clin Pathol 2010;63(2):151-5.
      OpenUrlAbstract/FREE Full Text
      1. Botto LD,
      2. May K,
      3. Fernhoff PM,
      4. Correa A,
      5. Coleman K,
      6. Rasmussen SA,
      7. et al
      . A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 2003;112(1 Pt 1):101-7.
      OpenUrlAbstract/FREE Full Text
    17. ↵
      1. Canaff L,
      2. Zhou X,
      3. Mosesova I,
      4. Cole DE,
      5. Hendy GN
      . Glial cells missing-2 (GCM2) transactivates the calcium-sensing receptor gene: effect of a dominant-negative GCM2 mutant associated with autosomal dominant hypoparathyroidism. Hum Mutat 2009;30(1):85-92.
      OpenUrlCrossRefPubMed
    18. ↵
      1. Urbano FL
      . Signs of hypocalcemia: Chvostek’s and Trousseau’s signs. Hosp Physician 2000;36(3):43-5.
      OpenUrl
    19. ↵
      1. Schaaf M,
      2. Payne CA
      . Effect of diphenylhydantoin and phenobarbital on overt and latent tetany. N Engl J Med 1966;274(22):1228-33.
      OpenUrlPubMed
    20. ↵
      1. Dickerson RN,
      2. Morgan LG,
      3. Cauthen AD,
      4. Alexander KH,
      5. Croce MA,
      6. Minard G,
      7. et al
      . Treatment of acute hypocalcemia in critically ill multiple-trauma patients. JPEN J Parenter Enteral Nutr 2005;29(6):436-41.
      OpenUrlAbstract/FREE Full Text
      1. Dickerson RN,
      2. Henry NY,
      3. Miller PL,
      4. Minard G,
      5. Brown RO
      . Low serum total calcium concentration as a marker of low serum ionized calcium concentration in critically ill patients receiving specialized nutrition support. Nutr Clin Pract 2007;22(3):323-8.
      OpenUrlAbstract/FREE Full Text
    21. ↵
      1. Dickerson RN,
      2. Alexander KH,
      3. Minard G,
      4. Croce MA,
      5. Brown RO
      . Accuracy of methods to estimate ionized and “corrected” serum calcium concentrations in critically ill multiple trauma patients receiving specialized nutrition support. JPEN J Parenter Enteral Nutr 2004;28(3):133-41.
      OpenUrlAbstract/FREE Full Text
    22. ↵
      1. Dickerson RN
      . Treatment of hypocalcemia in critical illness—part 1. Nutrition 2007;23(4):358-61.
      OpenUrlPubMed
    23. ↵
      1. Tohme JF,
      2. Bilezikian JP
      . Diagnosis and treatment of hypocalcemic emergencies. Endocrinologist 1996;6(1):10-8.
      OpenUrl
    24. ↵
      1. Body JJ,
      2. Bouillon R
      . Emergencies of calcium homeostasis. Rev Endocr Metab Disord 2003;4(2):167-75.
      OpenUrlCrossRefPubMed
    25. ↵
      1. Harvey JA,
      2. Zobitz MM,
      3. Pak CY
      . Dose dependency of calcium absorption: a comparison of calcium carbonate and calcium citrate. J Bone Miner Res 1988;3(3):253-8.
      OpenUrlPubMed
    26. ↵
      1. Eryol NK,
      2. Colak R,
      3. Ozdoğru I,
      4. Tanriverdi F,
      5. Unal S,
      6. Topsakal R,
      7. et al
      . Effects of calcium treatment on QT interval and QT dispersion in hypocalcemia. Am J Cardiol 2003;91(6):750-2.
      OpenUrlCrossRefPubMed
    27. ↵
      1. Hopper AD,
      2. Hadjivassiliou M,
      3. Butt S,
      4. Sanders DS
      . Adult coeliac disease. BMJ 2007;335(7619):558-62.
      OpenUrlFREE Full Text
    28. ↵
      1. Malabanan A,
      2. Veronikis IE,
      3. Holick MF
      . Redefining vitamin D insufficiency. Lancet 1998;351(9105):805-6.
      OpenUrlPubMed
    29. ↵
      1. Heaney RP,
      2. Davies KM,
      3. Chen TC,
      4. Holick MF,
      5. Barger-Lux MJ
      . Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003;77(1):204-10.
      OpenUrlAbstract/FREE Full Text
    30. ↵
      1. Tangpricha V,
      2. Koutkia P,
      3. Rieke SM,
      4. Chen TC,
      5. Perez AA,
      6. Holick MF
      . Fortification of orange juice with vitamin D: a novel approach for enhancing vitamin D nutritional health. Am J Clin Nutr 2003;77(6):1478-83.
      OpenUrlAbstract/FREE Full Text
    31. ↵
      1. Armas LA,
      2. Hollis BW,
      3. Heaney RP
      . Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004;89(11):5387-91.
      OpenUrlCrossRefPubMed
    32. ↵
      1. Trang HM,
      2. Cole DE,
      3. Rubin LA,
      4. Pierratos A,
      5. Siu S,
      6. Vieth R
      . Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998;68(4):854-8.
      OpenUrlAbstract
    33. ↵
      1. Trivedi DP,
      2. Doll R,
      3. Khaw KT
      . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326(7387):469.
      OpenUrlAbstract/FREE Full Text
    34. ↵
      1. Bouillon R,
      2. Norman AW,
      3. Lips P
      . Vitamin D deficiency. N Engl J Med 2007;357(19):1980-1.
      OpenUrlCrossRefPubMed
    35. ↵
      1. Noordzij M,
      2. Voormolen NM,
      3. Boeschoten EW,
      4. Dekker FW,
      5. Bos WJ,
      6. Krediet RT,
      7. et al
      . Disordered mineral metabolism is not a risk factor for loss of residual renal function in dialysis patients. Nephrol Dial Transplant 2009;24(5):1580-7.
      OpenUrlAbstract/FREE Full Text
    36. ↵
      1. Horwitz MJ,
      2. Stewart AF
      . Hypoparathyroidism: is it time for replacement therapy? J Clin Endocrinol Metab 2008;93(9):3307-9.
      OpenUrlCrossRefPubMed
    37. ↵
      1. Arlt W,
      2. Fremerey C,
      3. Callies F,
      4. Reincke M,
      5. Schneider P,
      6. Timmermann W,
      7. et al
      . Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 2002;146(2):215-22.
      OpenUrlAbstract
    38. ↵
      1. Winer KK,
      2. Yanovski JA,
      3. Cutler GB Jr.
      . Synthetic human parathyroid hormone 1–34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 1996;276(8):631-6.
      OpenUrlCrossRefPubMed
      1. Winer KK,
      2. Yanovski JA,
      3. Sarani B,
      4. Cutler GB Jr.
      . A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1–34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab 1998;83(10):3480-6.
      OpenUrlCrossRefPubMed
      1. Winer KK,
      2. Ko CW,
      3. Reynolds JC,
      4. Dowdy K,
      5. Keil M,
      6. Peterson D,
      7. et al
      . Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1–34) versus calcitriol and calcium. J Clin Endocrinol Metab 2003;88(9):4214-20.
      OpenUrlCrossRefPubMed
      1. Winer KK,
      2. Sinaii N,
      3. Peterson D,
      4. Sainz B Jr.,
      5. Cutler GB Jr.
      . Effects of once versus twice-daily parathyroid hormone 1–34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab 2008;93(9):3389-95. Epub 2008 May 20.
      OpenUrlCrossRefPubMed
    39. ↵
      1. Winer KK,
      2. Sinaii N,
      3. Reynolds J,
      4. Peterson D,
      5. Dowdy K,
      6. Cutler GB Jr.
      . Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1–34 versus calcitriol and calcium. J Clin Endocrinol Metab 2010;95(6):2680-8. Epub 2010 Apr 14.
      OpenUrlCrossRefPubMed
    40. ↵
      1. Rubin MR,
      2. Sliney J Jr.,
      3. McMahon DJ,
      4. Silverberg SJ,
      5. Bilezikian JP
      . Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int 2010;21(11):1927-34. Epub 2010 Jan 22.
      OpenUrlCrossRefPubMed
    41. ↵
      1. Rubin MR,
      2. Bilezikian JP
      . Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. Arq Bras Endocrinol Metabol 2010;54(2):220-6.
      OpenUrlCrossRefPubMed
    PreviousNext
    Back to top

    In this issue

    Canadian Family Physician: 58 (2)
    Canadian Family Physician
    Vol. 58, Issue 2
    1 Feb 2012
    • Table of Contents
    • About the Cover
    • Index by author
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Hypocalcemia
    (Your Name) has sent you a message from The College of Family Physicians of Canada
    (Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Hypocalcemia
    Jeremy Fong, Aliya Khan
    Canadian Family Physician Feb 2012, 58 (2) 158-162;

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Respond to this article
    Share
    Hypocalcemia
    Jeremy Fong, Aliya Khan
    Canadian Family Physician Feb 2012, 58 (2) 158-162;
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • Quality of evidence
      • Main message
      • Conclusion
      • Notes
      • Footnotes
      • References
    • Info & Metrics
    • eLetters
    • PDF

    Related Articles

    • Hypocalcémie
    • PubMed
    • Google Scholar

    Cited By...

    • Case 2: New-Onset Seizure in a 5-year-old Boy with Autism Spectrum Disorder
    • Factual or Factitious Hypocalcemia?
    • Google Scholar

    More in this TOC Section

    Practice

    • Is 45 the new 50 in colorectal cancer screening?
    • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
    • Determining if and how older patients can safely stay at home with additional services
    Show more Practice

    Clinical Review

    • Parkinson disease primer, part 1: diagnosis
    • Prescribing for common complications of spinal cord injury
    • Individualized antidepressant therapy in patients with major depressive disorder
    Show more Clinical Review

    Similar Articles

    Navigate

    • Home
    • Current Issue
    • Archive
    • Collections - English
    • Collections - Française

    For Authors

    • Authors and Reviewers
    • Submit a Manuscript
    • Permissions
    • Terms of Use

    General Information

    • About CFP
    • About the CFPC
    • Advertisers
    • Careers & Locums
    • Editorial Advisory Board
    • Subscribers

    Journal Services

    • Email Alerts
    • Twitter
    • RSS Feeds

    Copyright © 2023 by The College of Family Physicians of Canada

    Powered by HighWire